Search Within

Sloan Kettering Institute Faculty

  1. "Michael Morris"
Formats
  1. Journal Article (60)
  2. Meeting Abstract (52)
  3. Review (3)
Groups
  1. Department of Medicine (115)
  2. Genitourinary Oncology Service (115)
  3. Solid Tumor Oncology Division (115)
  4. GSK Faculty (112)
  5. Molecular Pharmacology and Chemistry Program Faculty (110)
  6. Molecular Imaging and Therapy Service (97)

More Groups

People
  1. Michael Morris (115)
  2. Howard Scher (96)
  3. Steven Larson (93)
  4. Susan Slovin (34)
  5. Neeta Pandit-Taskar (30)
  6. Josef Fox (29)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (6)
  5. 2021 (2)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (41)
  2. Journal of Nuclear Medicine (18)
  3. Clinical Cancer Research (10)
  4. Cancer (4)
  5. Cancer Research (3)
  6. Urology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (42)
  2. Society of Nuclear Medicine (18)
  3. American Association for Cancer Research (14)
  4. Springer (7)
  5. Elsevier Inc. (5)
  6. Elsevier Science, Inc. (5)

More Publishers

Results (115)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial study of bone scan tumor area for early surrogate outcome assessment in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Kim, H. J.; Brown, M. S.; Chu, G. H.; Gjertson, D. W.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload
    Meeting Abstract

    Dennis, E. R.; Fox, J. J.; Larson, S. M.; Farrelly, J. S.; Schwartz, L. H.; Schòˆder, H.; Haupt, E. C.; Borwick, L. S.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial analytic validation of automated bone scan measures for treatment response assessment in patients with metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Chu, G. H.; Brown, M. S.; Kim, H. J.; Auerbach, M.; Poon, C.; Ramakrishna, B.; Vidovic, A.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Automated tumor detection on bone scans for treatment response assessment
    Meeting Abstract

    Brown, M. S.; Chu, G. H.; Kim, H. J.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC)
    Meeting Abstract

    Baklajian, A.; Dennis, E. R.; Buddle, J. R.; Fox, J. J.; Schoder, H.; Morris, M. J.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload
    Meeting Abstract

    Morris, M. J.; Farrelly, J. S.; Fox, J. J.; Dennis, E. R.; Schwartz, L. H.; Schoder, H.; Haupt, E. C.; Borwick, L. S.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT
    Journal Article

    Fox, J. J.; Autran-Blanc, E.; Morris, M. J.; Gavane, S.; Nehmeh, S.; Van Nuffel, A.; Gonen, M.; Schoder, H.; Humm, J. L.; Scher, H. I.; more...
    Journal of Nuclear Medicine (2011)

    Fulltext@MSK | Save
  • Developing imaging strategies for castration resistant prostate cancer
    Journal Article

    Fox, J. J.; Morris, M. J.; Larson, S. M.; Schoder, H.; Scher, H. I.
    Acta Oncologica (2011)

    Fulltext@MSK | Save